PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2460815

Immunoreactive epitopes on human retinal S-antigen.

G Doekes·J P de Geus·J P Banga·J V Forrester·A Kijlstra
View original source ↗Export metadata ↓

Abstract

Although retinal S-antigen can induce experimental auto-immune uveitis in various animal species including primates, its role in clinical uveitis is not exactly known. More detailed knowledge on the immunoreactivity of human S-antigen might be of importance, since bovine S-antigen has been shown to carry both uveitogenic and non-uveitogenic epitopes. The number of immunoreactive epitopes on purified human S-antigen was therefore investigated in an inhibition ELISA with the use of a panel of four polyclonal and two monoclonal immune reagents. Assessment of their capacity to compete with each other for binding to the antigen resulted in complete, partial or no inhibition in the various combinations tested. Rabbit and rat anti-S-antigen immunoglobulins inhibited each other partially (up to 60%), from which the existence of at least three (groups of) epitopes was derived. Two monoclonal antibodies, of mouse (PDS-1) and rat (S.2.4C5) origin, did not inhibit each other, and thus defined two separate epitopes on human S-antigen. These epitopes belong to the set recognized by both rabbit and rat anti-S-antigen immunoglobulins since both monoclonals could be inhibited by rabbit and by rat antibodies. Epitopes detected by two mouse antisera also appeared to belong to this set. Thus, the existence of at least four immunoreactive sites on human S-antigen could be demonstrated.

Explore related subjects

Antibodies, MonoclonalAntigensArrestinEnzyme-Linked Immunosorbent AssayEpitopesEye ProteinsHumansJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Doekes, J P de Geus, J P Banga, J V Forrester, A Kijlstra. 1988. Immunoreactive epitopes on human retinal S-antigen.. https://doi.org/10.1159/000266656

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗
PubMed2008

Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.

Lymphoproliferative disease (LPD) is a complication of congenital and acquired immunodeficiency states. There are a number of treatment options for LPD arising after haematopoietic stem cell or solid organ transplantation including reduction of immunosuppression, targeted therapies, such as the anti-CD20 monoclonal antibody, rituximab, and EBV specific cytotoxic lymphocytes. Treatment of LPD in children with congenital immunodeficiency syndromes remains unsatisfactory and is associated with a high mortality rate. We recently managed an infant found to have polymorphic LPD concurrent with X-linked severe combined immunodeficiency (SCID). Haematopoietic stem cell transplantation (HSCT) had to be deferred because of progressive LPD. Treatment with rituximab resulted in regression of the LPD following which the patient received a 5/6 HLA matched umbilical cord blood (UCB) transplant. The patient remains well 20 months following transplantation. Rituximab treatment may have a useful role in the control of LPD associated with congenital immunodeficiency prior to HSCT.

Antibodies, Monoclonal↗
PubMed2008

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗